Posted by Michael Wonder on 06 Mar 2023
US FDA approves intramuscular administration for Merck’s MMRV family of vaccines: M-M-RII (measles, mumps and rubella virus vaccine live), Varivax (varicella virus vaccine live) and ProQuad (measles, mumps, rubella and varicella virus vaccine live)
6 March 2023 - With this additional route of administration, the MMRV family now joins other routinely recommended vaccines that can be administered intramuscularly.
Merck announced today that the US FDA has approved the addition of the intramuscular route of administration to the United States Product Insert for Merck’s MMRV family of vaccines: M-M-R II, Varivax and ProQuad.
